SYDNEY, Australia, March 31, 2026
Clarity Pharmaceuticals has announced the publication of Phase II Co-PSMA clinical trial results in the European Urology journal, demonstrating that its investigational imaging agent 64Cu-SAR-bisPSMA significantly outperforms standard-of-care PSMA PET imaging in detecting prostate cancer recurrence. The study highlights a more than twofold increase in lesion detection rates and substantial improvements in diagnostic accuracy, reinforcing the potential of this next-generation radiopharmaceutical imaging technology to transform prostate cancer diagnostics.
Superior Detection Rates and Diagnostic Accuracy
The Co-PSMA Phase II trial provided the first direct comparative evidence between 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT imaging, demonstrating a significant improvement in cancer lesion detection per patient (1.26 vs. 0.48, p < 0.0001). Additionally, the investigational agent identified a higher proportion of patients with positive scans (78% vs. 36%), confirming its enhanced sensitivity in detecting early biochemical recurrence of prostate cancer.
The study also showed that true positive detection rates were substantially higher (71% vs. 29%), while false-negative findings were significantly reduced. Importantly, the improved imaging capability translated into real-world clinical impact, with 44% of patients experiencing changes in treatment management, including shifts from observation to active therapy and modifications in radiation strategies.
Advanced Imaging Technology Enhances Clinical Decision-Making
Advertisement
The superior performance of 64Cu-SAR-bisPSMA is driven by its advanced imaging characteristics, including higher tumor uptake (SUVmax 13.6 vs. 5.3) and lower background signal, which significantly improves tumor-to-background contrast. These features enable clinicians to detect low-volume disease at earlier stages, particularly in patients with low prostate-specific antigen (PSA) levels, where traditional imaging methods often fail.
The study also demonstrated high inter-reader agreement (Cohen’s Kappa 0.94), indicating strong consistency and reliability in scan interpretation. This level of diagnostic confidence is critical in clinical practice, as it supports accurate treatment planning and improved patient outcomes. The findings suggest that this imaging approach could redefine diagnostic pathways in prostate cancer recurrence, enabling more precise and timely therapeutic interventions.
Clinical Impact and Future Development Pathway
The publication of Co-PSMA data in a leading peer-reviewed journal underscores the scientific credibility and clinical importance of the findings. The results build upon previous studies, including the COBRA and PROPELLER trials, and support ongoing development programs such as the Phase III AMPLIFY trial and the CLARIFY study, which aim to further validate the technology for regulatory approval.
Clarity’s SAR-bisPSMA platform represents a novel theranostic approach, combining diagnostic imaging and therapeutic potential using copper isotopes. The company is also preparing for future regulatory submissions, with plans to engage with the U.S. FDA and expand manufacturing capabilities to support large-scale commercial deployment.
Given that prostate cancer remains one of the most common and deadly cancers in men worldwide, advancements in early detection and accurate imaging are critical for improving survival outcomes and optimizing treatment strategies.
A Breakthrough in Prostate Cancer Imaging
The Co-PSMA trial results position 64Cu-SAR-bisPSMA as a next-generation imaging agent with the potential to significantly improve prostate cancer detection and management, offering a powerful tool for precision oncology. As clinical development progresses, this innovation could play a pivotal role in enhancing diagnostic accuracy, guiding treatment decisions, and ultimately improving patient outcomes.
Source: Clarity Pharmaceuticals press release
